Page 249 - FBL AR 2019-20

Brief profile of Directors being appointed or re-appointed, as required under regulation 26(4), 36(3) of the Listing Regulations and
Secretarial Standard on General Meetings specified by the Institute of Company Secretaries of India and approved by the Central
Government
Name of the Director Ms. Rajeshwari Datla Mr. Satish Varma Ms. Anupama Datla Desai Ms. Rajashri Ojha
Non-Executive Executive Director Executive Director Additional
Director (Independent)
Director
Age 70 years 50 years 42 years 52 years
Date of first appointment on July 21, 2005 July 01, 2003 September 27, 2019 April 01, 2020
the Board
Qualifications Bachelor of Science Computer Science Post-Graduate in Bachelor of Pharmacy
Biotechnology from
Mumbai University and
Science Graduate from the
Boston College, USA.
Experience and Area of 40 years of experience. 23 years of experience. 14 years of experience. 30 years of experience.
specialization Rich management Extensive and diverse Quality control and Pharmaceutical,
and operational operational, management and implementation of safety Medical devices, Nutra
and experience legal experience across the full policies and procedures industry including
in Pharmaceutical scope of the FBL enterprise and across the organization. in R&D analytical
Industry and has been was instrumental in the Solvay In charge of introducing development,
instrumental in FBL’s demerger in 2000 as well as the and implementing new formulations
journey till date Crocin brand outlicence in 1996, technology platforms development,
events that have shaped the into the company and regulatory & QA
current strategic platform of the also spearheads the new compliance and Global
Company. business development, registrations and
Took direct operational customer interaction and marketing approvals
responsibility of the Vitamin D3 marketing in India and for Pharma, Biotech,
business in 1998 and has led its overseas. Medical Devices,
growth. Nutraceuticals, OTC
products world-wide.
Number of meetings of the 8 8 2 Not Applicable as she
Board of the Company attended was appointed w.e.f.
during FY 2019-20 April 01, 2020
Directorship held in other • Dupen Laboratories • G I Biotech Private Limited; • Dupen Laboratories • Raaj GPRAC Private
companies Private Limited • Aegean Properties Limited; Private Limited; Limited
• Lacto Cosmetics • DVK Investments Private • Lacto Cosmetics (Vapi)
(Vapi) Private Limited Limited; Pvt. Ltd.
• CC Square Films Limited;
• Fermenta Biotech (UK) Limited
Chairmanships/Memberships of Nil Nil Nil Nil
Committee* of other Company’s
Boards (as on March 31, 2020)
Terms and conditions of N.A. As stated in the explanatory As stated in the As stated in the
appointment along with statement to the Notice explanatory statement to explanatory statement
remuneration proposed to be the Notice to the Notice
paid and Remuneration last
drawn
Shareholding of Director (FV of 5,09,718 equity shares 23,160 equity shares 4,05,492 equity shares Nil
Rs. 5/- each) (as on March 31,
2020)
Relationship with other Mother of Mr. Nil As mentioned in the Nil
Directors, Manager and other Krishna Datla and Ms. explanatory statement to
Key Managerial Personnel of the Anupama Datla Desai the Notice
Company
* Audit Committee, Corporate Social Responsibility Committee, Stakeholders Relationship Committee, and Nomination and Remuneration Committee.

247